loading...| Preferred Name | saquinavir mesylate | |
| Synonyms |
Invirase |
|
| Definitions |
The mesylate salt form of saquinavir, a synthetic peptidomimetic substrate with antiviral property. Saquinavir selectively binds to and inhibits human immunodeficiency virus type 1 (HIV-1) protease, an aspartic protease that cleaves viral gag and gag-pol polyprotein (precursors for viral proteases, reverse transcriptase, and integrase). Inhibition of HIV-1 protease prevents functional viral proteins to be cleaved from the viral polyprotein precursor and results in the release of immature, noninfectious virions. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1602" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1602" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000042693 |
|
| altLabel |
Invirase |
|
| CAS Registry |
149845-06-7 |
|
| cui |
C0701215 C0286737 |
|
| definition |
The mesylate salt form of saquinavir, a synthetic peptidomimetic substrate with antiviral property. Saquinavir selectively binds to and inhibits human immunodeficiency virus type 1 (HIV-1) protease, an aspartic protease that cleaves viral gag and gag-pol polyprotein (precursors for viral proteases, reverse transcriptase, and integrase). Inhibition of HIV-1 protease prevents functional viral proteins to be cleaved from the viral polyprotein precursor and results in the release of immature, noninfectious virions. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1602" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1602" NCI Thesaurus) |
|
| Legacy PDQ ID |
6483 |
|
| LT |
TRD |
|
| NCI ID |
C1602 |
|
| notation |
CDR0000042693 |
|
| NSC Code |
722663 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
saquinavir mesylate |
|
| tui |
T109 T121 |